Cargando…

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC

BACKGROUND: PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chiao-En, Chang, Ching-Fu, Kou-Sheng, Liao, Chiang, Ju, Lee, Shih-Wei, Chiu, Yu-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655253/ https://www.ncbi.nlm.nih.gov/pubmed/33204603 http://dx.doi.org/10.1155/2020/3286139

Ejemplares similares

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

A high density of PD-L1-expressing immune cells is significantly correlated with favorable disease free survival in nonmetastatic colorectal cancer
por: Kuo, Ya-Ting, et al.
Publicado: (2022)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
por: Inge, L.J., et al.
Publicado: (2020)

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review
por: Koomen, Bregje M, et al.
Publicado: (2020)

Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma
por: Kang, So Young, et al.
Publicado: (2022)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
por: Sánchez-Gastaldo, Amparo, et al.
Publicado: (2021)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
por: Toral, Keller J., et al.
Publicado: (2021)

Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry
por: Shinchi, Yusuke, et al.
Publicado: (2019)

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR
por: Alwithenani, Akram, et al.
Publicado: (2021)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
por: Gauvin, Camille, et al.
Publicado: (2021)

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
por: Cefalì, Marco, et al.
Publicado: (2022)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
por: Yi, Ling, et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ovf55qdcin9ht1tlrqn6e3k9v